TGF-b is long considered a ''protean'' cytokine in cancer, changing its role from anti-to pro-tumorigenic in a context-dependent manner. In this issue of Cell, David et al. use mouse models of pancreatic cancer to shed light on the mechanistic basis of how TGF-b-induced EMT is coupled to either apoptosis or tumor progression.
Epithelial-to-mesenchymal transition (EMT) is a reversible cellular process promoting invasiveness, traditionally believed to be the prelude to the process of metastasis, wherein cells within a primary tumor lose their epithelial characteristics and acquire both the phenotype and a transcriptional program reminiscent of mesenchymal cells (Kalluri and Weinberg, 2009 ). In contrast to adherent, sheet-like epithelial cells, mesenchymal cells lack apical polarity, lose their intercellular tight junctions, and secrete extracellular-matrix-degrading enzymes (such as metalloproteinases), rendering them capable of enhanced motility and invasive properties in vitro and competent for the metastatic cascade in vivo (Reymond et al., 2013) . During the process of EMT, there is evident cytoskeletal reorganization, accompanied by changes in expression of multiple transcription factors, surface receptors, and secreted ligands, which together contribute to the phenotypic manifestations of EMT (Kalluri and Weinberg, 2009) . Apart from its ascribed role in the process of metastasis, EMT has also been attributed to enhancing a cancer stem cell (CSC)-like phenotype within the neoplastic population, in conferring resistance to chemotherapeutic agents, and in enabling survival under conditions of extraneous stress, such as nutrient deprivation (Singh and Settleman, 2010) .
One of the best known inducers of EMT in cultured epithelial cells is transforming growth factor-b (TGFb), which, paradoxically, is known to be a growth suppressor in non-neoplastic epithelium but a tumor promoter in advanced cancers (Hanahan and Weinberg, 2011) . In cell culture experiments, TGFb ligand, acting in either a autocrine or paracrine manner, binds to cognate receptors on the cancer cell surface and mediates its signal through the Smad transactivator family of proteins to transcription factors such as Snail, Slug, Twist, or Zeb1 in inducing EMT (Hanahan and Weinberg, 2011) . TGFb has potent growth inhibitory effects on nonneoplastic epithelial cells, where it hinders cell proliferation by blocking cell-cycle progression at the G1 phase and by enabling suppression of oncogenic signals, such as Myc (Hanahan and Weinberg, 2011) . During later stages of carcinogenesis, TGFb augments cancer invasion and metastasis through effects on various cellular populations within the tumor microenvironment, such as stromal cells, endothelial cells, and immune cells, promoting stromal ''activation'' and angiogenesis, while suppressing a productive anti-tumor immune response (Hanahan and Weinberg, 2011) . Other than such paracrine effects, however, the cell intrinsic role of TGFb engagement with cancer cells has been less obvious, although the prevailing assumption has been that of induction of a ''metastasis-promoting'' EMT as the most consistent outcome.
In this issue of Cell, David et al. (2016) provide elegant mechanistic data to elucidate the dichotomous effects of TGFb on pancreatic ductal adenocarcinoma (PDAC) cells (Figure 1 ). Specifically, under conditions of TGFb stimulation, absence of the common transactivator protein Smad4 in PDAC cells promotes tumor growth, while in its presence cancer cells undergo apoptosis. Notably, Smad4 inactivation is present in nearly half of PDAC cases, and its tissue-specific deletion accelerates cancer progression in the oncogenic Kras-driven genetically engineered mouse model (GEMM) of pancreatic cancer (Bardeesy et al., 2006) . What is surprising is that TGFb-induced Smad4-dependent apoptosis is still preceded by EMT. Moreover, TGFb-induced transcription factors Snail and Zeb1 were necessary for this EMT-related apoptosis in Smad4-expressing cells. Furthermore, in a PDAC GEMM in which mutant Kras expression in pancreas drives premalignant pancreatic precursor lesions, loss of either one or both copies of Snail did not hinder development of in situ carcinoma and even led to metastasis in one of the mice.
Further probing for additional TGFb-induced factors that cooperate with Snail in cell death induction led David et al. to a transcription factor, Sox4, known to be important during tissue specification and present in epithelial progenitor cells of pancreatic, intestinal, uterine, and mammary tissues. They found that, while Sox4 was required for TGFb-induced Smad4-mediated apoptosis, it had no direct effect on the preceding EMT. In the absence of TGFb-induced EMT, however, Sox4, consistent with its role as an epithelial progenitor factor, actually supported the tumor-initiating capacity of PDAC cells. Another striking observation was that Klf5, an important epithelial lineage survival factor for PDAC, cooperated with Sox4 in preventing apoptosis in the absence of TGFb-induced EMT. Surprisingly, even in Smad4-null cells, loss of Klf5 was sufficient to revert the protumorigenic effects of TGFb and induce apoptosis. Lastly, they established that, upon TGFb-mediated EMT in Smad4-positive cells, EMT transcription factors Snail and Zeb1 downregulated Klf5 expression in conjunction with Smad4-dependent Smad2/3, thus converting Sox4 from an anti-apoptotic to proapoptotic factor.
This study clarifies the basis for the paradoxical dichotomy in TGFb effects on cancer cells, with Smad4-dependent ''lethal'' EMT altering a pro-tumorigenic transcriptional program to a pro-apoptotic one via Snail-and Zeb1-induced downregulation of Klf5. Interestingly, the observation that conditional SNAI1 knockout PDAC retains metastatic competency is also consistent with recent reports in which both pancreatic and breast cancers cells retain their ability to metastasize regardless of EMT (Fischer et al., 2015; Zheng et al., 2015) . This challenges the long-held assumption that, as cells with a mesenchymal phenotype have greater invasive properties in vitro, the process of EMT is required for metastasis of epithelial tumor cells in vivo. Furthermore, this finding may also provide: (1) an explanation for the well-established observation that most PDAC metastases are not inherently mesenchymal, obviating the need to invoke a reverse mesenchymalto-epithelial transition (MET) phenomenon, and (2) a possible mechanistic explanation for the prior empirical observation that, in terminal PDAC, cancers with loss of SMAD4 tend to be widely metastatic, while those with retained Smad4 function are often oligometastatic. Finally, the study may provide insight into the factors driving the success of the metastatic process, given that the majority of the disseminated cells undergo apoptosis and only a minor fraction of surviving cells establish productive metastatic foci (Chambers et al., 2002) .
However, there remain some unanswered questions about the persistent significance of EMT in cancer. For example, while EMT may be dispensable for metastases, it has been shown to contribute to chemoresistance (Fischer et al., 2015; Zheng et al., 2015) , and it is unclear how ''lethal'' EMT might be reconciled with this observed resistance to therapy. One could speculate that, in contrast with in vitro conditions of stimulation, physiological TGFb levels might cause a ''partial EMT'' that confers treatment refractoriness without triggering apoptosis. It might be important to evaluate how graded exposure to TGFb influences cell fate, versus an all-ornone outcome. Further, as TGFb is only one of the several inducers of EMT (albeit the most commonly studied analyte in this phenomenon), it remains to be seen whether EMT initiated by other ligands in Smad4-positive cells will similarly lead to apoptosis. Finally, from a translational standpoint, this study elucidates the context-dependent importance of KLF5 as a transcription factor facilitating cancer progression. In tumors such as SMAD4 mutant pancreatic cancers, small-molecule inhibitors of KLF5 (Bialkowska et al., 2011) could become an important therapeutic avenue as antimetastatic agents.
Axon degeneration in response to trophic deprivation was thought to be locally restricted to the axon. However, increasing evidence points to a requirement for the cell body in the degenerative program. Now, Simon et al. identify the pro-apoptotic protein Puma as a key factor in this cell body-derived signal.
In animal development, the immature nervous system grows an overabundance of axonal projections, the majority of which are pruned back by competition for limited target-derived signals such as neurotrophins. Axons that are outcompeted by their neighbors or fail to find their targets die back through a process known as axonal degeneration, which serves to optimize the nervous system and to ensure that only functional connections are maintained. Axon degeneration also happens in the mature nervous system in response to damage or disease, thus an understanding of the molecular mechanisms of this process has potential relevance for neural injury and neurodegenerative conditions. In the past few decades, great inroads have been made into the molecular mechanism of developmental axonal degeneration using the trophic deprivation paradigm, but it remained debatable whether this process was simply a local, axonal phenomenon or if it required signals from the cell body.
In this issue of Cell, Simon and colleagues provide convincing evidence that de novo transcription of proapoptotic protein Puma is required for axon degeneration in response to trophic deprivation (Simon et al., 2016) . The authors systematically examined the known players in this form of axon degeneration, essentially tracing incoming emergency signals from the axon back to the central Mission Control of the cell body, which then sends out a destruction command to the axon (Figure 1) . Along the way, their data also resolve several previously conflicting observations about axon degeneration induced by trophic deprivation.
Prodigious effort has gone into teasing apart the signaling molecules involved in axon degeneration and so far the data point to somewhat parallel pathways at work (Pease and Segal, 2014) . Intriguingly, different pathways may be engaged depending on the nature of the insult; for example, pathways involved in developmental degeneration or pruning, tested with trophic deprivation in embryonic cultures, may not be the same pathways involved in response to trauma, such as axotomy (Luo and O'Leary, 2005) .
In the context of developmental axon degeneration, recent studies have established signaling roles for MAP kinases DLK and JNK, and caspases, although the role of the apoptotic machinery has been a point of debate (Cusack et al., 2013; Freeman, 2014; Pease and Segal, 2014) . Specifically, caspases and other proteolytic molecules are present within axons, and local trophic deprivation using compartmented cultures results in axon degeneration, so it was assumed that this is a local process not involving the
